List of Zemdri drug patents

Zemdri is owned by Cipla Usa.

Zemdri contains Plazomicin Sulfate.

Zemdri has a total of 4 drug patents out of which 0 drug patents have expired.

Zemdri was authorised for market use on 25 June, 2018.

Zemdri is available in solution;intravenous dosage forms.

Zemdri can be used as method of using plazomicin to treat bacterial infections.

Drug patent challenges can be filed against Zemdri from June, 2027.

The generics of Zemdri are possible to be released after 02 June, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9688711 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US8383596 CIPLA USA Antibacterial aminoglycoside analogs
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9266919 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US8822424 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 25, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 25, 2028

Drugs and Companies using PLAZOMICIN SULFATE ingredient

NCE-1 date: June, 2027

Market Authorisation Date: 25 June, 2018

Treatment: Method of using plazomicin to treat bacterial infections

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in